Severe aortic stenosis (AS), also known as heart valve failure, can progress rapidly and unpredictably1-4

25% of asymptomatic patients under watchful waiting required AVR within 6 months due to symptom onset

of asymptomatic patients under watchful waiting required AVR within 6 months due to symptom onset4


40% of patients presented with advanced signs and symptoms at the time of AVR conversion

of patients presented with advanced signs and symptoms at the time of AVR conversion4

Icon showing 1 in 10 symptomatic severe AS patients may die within 5 weeks without intervention

DELAYED REFERRAL MEANS PUTTING PATIENTS AT RISK1

1 in 10 symptomatic severe AS patients may die within 5 weeks without intervention.* Earlier referrals and intervention could prevent these deaths.1

*After recommendation for AVR.1

Don’t let fixable become fatal. Because severe AS can lead to a decline in your patients’ health quickly and without warning, it’s important to refer to a Heart Valve Team promptly upon diagnosis.1-4

Peer Perspectives:

The importance of referring your severe AS patients at the right time

Watch video

To watch more Peer Perspectives, visit our Featured Videos page.

Stay informed

Sign up for our newsletter to get the latest news about Edwards and heart valve health.

Sign up for the newsletter
Icon of a brochure

Find helpful resources

Download informative materials for your patients and your practice.

Visit our resource library
Icon of a discussion guide
References: 1.Malaisrie SC, McDonald E, Kruse J, et al. Mortality while waiting for aortic valve replacement. Ann Thorac Surg. 2014;98(5):1564-1571. 2.Coisne A, Montaigne D, Aghezzaf S, et al. Association of mortality with aortic stenosis severity in outpatients: results from the VALVENOR study. JAMA Cardiol. 2021;6(12):1424-1431. 3.Généreux P, Pibarot P, Redfors B, et al. Staging classification of aortic stenosis based on the extent of cardiac damage. Eur Heart J. 2017;38(45):3351-3358. 4.Généreux P, Schwartz A, Oldemeyer JB, et al. Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N Engl J Med. 2025;392(3):217-227. 5.Benfari G, Essayagh B, Michelena HI, et al. Severe aortic stenosis: secular trends of incidence and outcomes. Eur Heart J. 2024;45(21):1877-1886. 6.Li SX, Patel NK, Flannery LD, et al. Trends in utilization of aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol. 2022;79(9):864-877. 7.Lindman BR, Lowenstern A. The alarm blares for undertreatment of aortic stenosis: how will we respond? J Am Coll Cardiol. 2022;79(9):878-881. 8.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705. 9.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023;389(21):1949-1960. 10.Nazif TM, Cahill TJ, Daniels D, et al. Real-world experience with the SAPIEN 3 Ultra transcatheter heart valve: a propensity-matched analysis from the United States. Circ Cardiovasc Interv. 2021;14(9):e010543.

Patients and/or clinicians quoted on this website have received compensation from Edwards Lifesciences.